Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils

Conclusions Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research